Eris Lifesciences Ltd (BOM:540596)
₹ 1353.8 11.3 (0.84%) Market Cap: 184.29 Bil Enterprise Value: 213.23 Bil PE Ratio: 52.93 PB Ratio: 6.65 GF Score: 93/100

Q2 2022 Eris Lifesciences Ltd Earnings Call Transcript

Oct 29, 2021 / 10:30AM GMT
Release Date Price: ₹817.3 (+4.44%)
Amit Indubhushan Bakshi
Eris Lifesciences Limited - Chairman & MD

Thank you. Am I audible?

Operator

Yes, sir.

Krishnakumar Vaidyanathan
Eris Lifesciences Limited - Executive Director & COO

Great. Good afternoon, everyone, and welcome to our second quarter conference call. I'm Krishnakumar, and I'm happy to share the highlights of the quarter with you. As per the AIOCD retail audit, Indian pharma market grew at 15% in quarter 2 of this year, but this was on a low base of 1% growth in quarter 2 of last year. The 15% growth in quarter 2 was once again led by acute therapies, which enjoyed the benefit of a low base effect from last year, along with the surge of infections like H1N1, Dengue and Chikungunya after the wave 2 of COVID subsided.

I'm happy to share that Eris grew at 11.4% in quarter 2 of this year on top of a 7.4% growth in quarter 2 of last year. We have also been looking at how our business has performed from pre-COVID levels. The Indian pharma market, from its pre-COVID level, has grown at a CAGR

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot